• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Novo Nordisk A>Novo Nordisk A/S ADR

Novo Nordisk A/S ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. NVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017

    NVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017

  2. Robbins Arroyo LLP: Novo Nordisk A/S (NVO ) Misled Shareholders According to a Recently Filed Class Action

    Robbins Arroyo LLP: Novo Nordisk A/S ( NVO ) Misled Shareholders According to a Recently Filed Class Action

  3. What We Can Expect From Second-Quarter Earnings

    Morningstar's Heather Brilliant says investors could see a lot of market volatility this upcoming earnings season, but that could make for tremendous buying opportunities of quality names.

  4. Sanofi Shakes Off Patent Losses

    The drugmaker faces less long-term volatility as the focus shifts to steady businesses.

  5. Finding a Margin of Safety in a Fully Valued Market

    These three wide-moat firms are trading at reasonable prices in a market with little breathing room in valuations.

  6. 6 Key Concepts to Stock Investing Defined

    From moats to fair value to stewardship, we explain the key pillars of our approach to equities.

  7. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  8. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  9. Moats and Growth Drivers Look Solid for Post-Split Baxter

    Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

  10. Makings of a Wide Moat in Diabetes Care

    Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

123

©2017 Morningstar Advisor. All right reserved.